B of A Securities analyst Jason Zemansky maintains a Neutral rating on Biogen (NASDAQ: BIIB) while adjusting the stock's valuation expectations. The firm lowered the price target to $215 from the previous $217, reflecting a revised outlook on the pharmaceutical company's shares.

The rating action follows a review of Biogen's current market position and future performance potential. Despite the reduction in the price target, the Neutral stance suggests the stock is expected to perform in line with the broader market rather than significantly outperform or underperform in the near term.

Price Target Revision

The adjustment represents a modest decrease in the projected valuation for Biogen shares. The following table details the revised analyst metrics:

Biogen Inc. has appointed Michael J. Parini as Chief Legal Officer, effective August 3, 2026, to strengthen its leadership team as the company pursues renewed growth. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, he will assume responsibility for the oversight of Biogen’s global legal and compliance functions.

Parini joins Biogen with more than 20 years of senior legal and strategic leadership experience across the biopharmaceutical and biotechnology industry. Most recently, he served as Chief Executive Officer of Spur Therapeutics, where he led a company transformation, redefining the scientific strategy and advancing a rare disease program from the pre-clinical stage into Phase 3 development.

Prior to his tenure at Spur Therapeutics, Parini held a series of leadership roles at Vertex Pharmaceuticals, rising to Chief Administrative, Legal and Business Development Officer. He served on the Executive Committee and oversaw multiple functions spanning Legal, Compliance, Business Development, Human Resources, Information Technology, Quality and Corporate Communications. During his time at Vertex, he helped lead the acquisitions of Exonics Therapeutics and Semma Therapeutics, as well as the negotiation of market access agreements for cystic fibrosis medicines across the United Kingdom, France, Italy, Australia, and Spain.

Before Vertex, Parini held multiple senior roles in the legal function at Pfizer, including Chief Litigation Counsel. He holds a J.D. from Georgetown University Law and a B.A. in American Government and Politics from Georgetown University.

Executive Background